Disease · MONDO_0006004
vasomotor rhinitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. vasomotor rhinitis. Diseases, record MONDO_0006004. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006004
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AZELASTINE HYDROCHLORIDE | CHEMBL1200809 | Small molecule | Approval | DailyMed | 6 | 0 | 0 | Drugs and targets |
| CARBINOXAMINE MALEATE | CHEMBL1200974 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| DEXCHLORPHENIRAMINE MALEATE | CHEMBL1200927 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| FLUTICASONE FUROATE | CHEMBL1676 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LEVOCETIRIZINE | CHEMBL1201191 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PSEUDOEPHEDRINE | CHEMBL1590 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HRH1 | Histamine H1 receptor | 4 | Histamine H1 receptor antagonist | Approval | https://conductscience.org/library/genes/3269 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 1 | Norepinephrine transporter releasing agent | Phase 3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
Trials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00117325 | Study Of Adults And Adolescents With Vasomotor Rhinitis | Phase 3 | 352 | 2018-03-13 | Rhinitis, Vasomotor | FLUTICASONE FUROATE | Its record names the disease | ClinicalTrials.gov |
| NCT00118703 | Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis | Phase 3 | 350 | 2017-05-02 | Vasomotor Rhinitis, Rhinitis, Vasomotor | FLUTICASONE FUROATE | Its record names the disease | ClinicalTrials.gov |
| NCT01509209 | Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis | Phase 3 | 137 | Vasomotor Rhinitis | LEVOCETIRIZINE, PSEUDOEPHEDRINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Fluticasone Furoate 110mcg QD vs Placebo: deaths from any cause | 0 of 179 | 0 of 173 | 352 | NCT00117325 | Trial comparisons |
| Fluticasone Furoate 110mcg QD vs Placebo: serious adverse events | 0 of 179 | 0 of 173 | 352 | NCT00117325 | Trial comparisons |
| Fluticasone Furoate 110 µg QD vs Placebo: deaths from any cause | 0 of 174 | 0 of 173 | 347 | NCT00118703 | Trial comparisons |
| Fluticasone Furoate 110 µg QD vs Placebo: serious adverse events | 1 of 174 | 0 of 173 | 347 | NCT00118703 | Trial comparisons |
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006004
GET https://conductscience.org/api/diseases/v1/MONDO_0006004/drugs